Claims

Consumers should submit FTC comments supporting the petition by mentioning that they want the rule reopened to consider technical issues raised by audioholics and the CTA, and should use the slogan 'one measurement to not rule them all' to emphasize that different system types require different testing conditions.

In 2000, the FTC removed the mandate for power specification disclosure in advertising media for amplifiers, though manufacturers still had to disclose specifications in product sheets and manuals, giving them freedom to inflate power claims in advertisements by amounts up to twice the actual FTC-compliant power.

In 2020, the FTC was considering eliminating the amplifier rule entirely, but consumer advocacy (including from audioholics' 'Truth and Power' movement) resulted in over 1,133 public comments supporting the rule, which led the FTC to keep it in place as a check and balance on industry practices.

The 2024 FTC amplifier rule requires amplifier power to be tested at 8 ohms load impedance regardless of the actual impedance of the loudspeaker or system being driven, meaning that if a subwoofer driver is 4 ohms, the amplifier must still be rated at 8 ohms, which results in derating the amplifier and misrepresenting its actual power delivery capability in the system for which it was designed.

The August 12, 2024 effective date of the FTC rule creates urgent compliance challenges for manufacturers who had already committed to marketing and product launches, as products manufactured and packaged before the date could become non-compliant if sold afterward, posing significant legal risks.

The 5-minute testing requirement in the FTC rule lacks clear specification about how to conduct the test: whether it should be a continuous 5-minute sine wave at 1kHz followed by a sweep from 20Hz to 20kHz, or some other configuration, creating ambiguity that is self-defeating and requires more clarification.

The FTC comment period for the petition to reopen the rule has a deadline of November 8th (at the time of the video), creating an urgent, time-sensitive call to action for consumers to submit comments supporting the petition.

The rule provides no guidance on how to specify power for multi-channel amplifiers with more than two channels driven, despite the FTC wrestling with this issue for many years and receiving presentations on this topic.

A system designed within a specific bandwidth should be tested within that pass band, not across the full 20 Hz to 20 kHz range mandated by the FTC, to avoid unrealistic testing conditions for frequency-limited designs.

The FTC should establish an exemption for products manufactured, packaged, and marketed before August 12, 2024 to clarify that the retroactive application of the new rule will not apply to existing inventory and specifications.

Gensler weaponized the SEC to treat Ripple differently from Ethereum despite similar properties, winning a court case but then tripling down on the same losing legal theory, demonstrating arbitrary and capricious regulatory abuse

Prediction markets should remain legal but require more regulation to prevent thin trading and undue manipulation while maintaining open access for broader participation

SEC has been issuing Wells notices against virtually all sizable US crypto corporations while Biden administration vetoes pro-crypto legislation, signaling coordinated regulatory hostility toward crypto.

The FDA has a global stranglehold on biotech regulation; most governments follow FDA standards rather than establishing looser alternatives, reducing regulatory arbitrage opportunities.

eBay's unregulated pre-9/11 environment (1999-2000) allowed PayPal to operate without strict know-your-customer requirements; post-9/11, regulatory constraints would have made PayPal's rapid scaling impossible, suggesting the company could not have been started after 2001 or perhaps even in late 2000.

The FDA has a 'global stranglehold' on biotech development because most governments are unwilling to have regulations looser than the FDA's, and because US pharma markets pay more, most biotech is developed for the US market regardless of origin; regulatory arbitrage is much smaller than it appears.

One explanation for technological stagnation is the FDA's regulatory approach to drug approval, which is so restrictive that if video games were regulated with equivalent rigor, we would still be playing Pong, illustrating how regulatory burden suppresses innovation.